Search
for
Sort by
Research 30 of 1000+
- 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
- JAK inhibition in the treatment of alopecia areata – a promising new dawn?
- The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm
- Systemic treatments for alopecia areata: A systematic review
- New drugs under investigation for the treatment of alopecias
- Janus kinase inhibitors for alopecia areata: a review of clinical data
- Janus Kinase inhibitors in dermatology: a review
- New therapies for alopecia areata
- The role of janus kinases in the treatment of autoimmune skin diseases
- Clinical Trials and Hair Loss
- Alopecia areata: from immunopathogenesis to emerging therapeutic approaches
- Clinical Assessment of Alopecia Areata Severity and Validating the Patient Experience: A Vodcast
- Common Causes of Hair Loss and Their Treatment Options
- Small Molecule Inhibitors and Inflammatory Skin Diseases
- Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
- Targeting the Janus Kinase Family in Autoimmune Skin Diseases
- Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata
- 0527 Effectiveness of janus kinase inhibitor for rapidly progressive acute alopecia areata
- The JAK/STAT signaling pathway: from bench to clinic
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- JAK Inhibitors for Treatment of Alopecia Areata
- Alopecia Areata: Current Treatments and New Directions
- Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
- Cyclosporine for moderate-to-severe alopecia areata: A double-blind, randomized, placebo-controlled clinical trial of efficacy and safety
- Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers
- Alopecia Areata: Pathogenesis, Diagnosis, and Therapies
- A phase 2a trial of brepocitinib for cicatricial alopecia
- The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature
- Immunopathology and Immunotherapy of Inflammatory Skin Diseases
- Alopecia areata – Current understanding and management